ALK+ inflammatory myofibroblastic tumor
Image Gallery
[ (||image_reduire{0,60}|inserer_attribut{alt,ALK immunolabelling in myofibroblastic inflammatory tumor}) ] [ (||image_reduire{0,60}|inserer_attribut{alt,ALK immunolabelling in myofibroblastic inflammatory tumor}) ] [ (||image_reduire{0,60}|inserer_attribut{alt,ALK immunolabelling in myofibroblastic inflammatory tumor}) ] [ (||image_reduire{0,60}|inserer_attribut{alt,ALK immunolabelling in myofibroblastic inflammatory tumor}) ] [ (||image_reduire{0,60}|inserer_attribut{alt,Pulmonary myofibroblastic inflammatory tumor}) ] [ (||image_reduire{0,60}|inserer_attribut{alt,Pulmonary myofibroblastic inflammatory tumor}) ]
Inflammatory myofibroblastic tumour has been allocated to the intermediate (rarely metastasizing) category.
They are regarded as neoplasms which, in children, are quite often characterized by ALK-1 gene rearrangements, and which may recur or metastasize in as many as 5% of cases. Unfortunately, aggressive behaviour cannot always be predicted on morphological grounds.
Localization
soft tissues
urinary bladder
uterus (#16160478#)
Variants
neonatal case (#15991166#, #14577098#, #12574774#)
aggressive inflammatory myofibroblastic tumour
atypical inflammatory myofibroblastic tumour
Prognosis
rare metastases (#15747099#)
- rare pulmonary metastases (#15747099#)
Immunochemistry
smooth muscle actin + (SMA +)
ALK + (#11684952#)
Cytogenetics
2p23 rearrangement (ALK)
- 19p13.1 (TPM4)
- 1q22.23 (TPM3)
- 17q23 (CLTCL2)
Molecular biology
ALK/TPM4 fusion gene ( at 19p13.1)
ALK/TPM3 fusion gene(at 1q22.23)
ALK/CLTCL2 fusion gene (at 17q23)
ALK/CARS fusion gene (#13679433#)
See also
inflammatory pseudotumor
References
Inflammatory myofibroblastic tumor versus IgG4-related sclerosing disease and inflammatory pseudotumor: a comparative clinicopathologic study. Yamamoto H, Yamaguchi H, Aishima S, Oda Y, Kohashi K, Oshiro Y, Tsuneyoshi M. Am J Surg Pathol. 2009 Sep;33(9):1330-40. PMID: #19718789#
Inflammatory myofibroblastic tumor: comparison of clinicopathologic, histologic, and immunohistochemical features including ALK expression in atypical and aggressive cases. Coffin CM, Hornick JL, Fletcher CD. Am J Surg Pathol. 2007 Apr;31(4):509-20. PMID: #17414097#
The evolving classification of soft tissue tumours: an update based on the new WHO classification. Fletcher CD. Histopathology. 2006 Jan;48(1):3-12. PMID: #16359532#
Mergan F, Jaubert F, Sauvat F, et al. Inflammatory myofibroblastic tumor in children: clinical review with anaplastic lymphoma kinase, Epstein-Barr virus, and human herpesvirus 8 detection analysis. J Pediatr Surg 2005;40:1581–1586.
Yamamoto H, Oda Y, Saito T, et al. p53 Mutation and MDM2 amplification in inflammatory myofibroblastic tumours. Histopathology 2003;42:431–439.
Identification of CARS-ALK fusion in primary and metastatic lesions of an inflammatory myofibroblastic tumor. Debelenko LV, Arthur DC, Pack SD, Helman LJ, Schrump DS, Tsokos M. Lab Invest. 2003 Sep;83(9):1255-65. PMID: #13679433#
Cook JR, Dehner LP, Collins MH, Ma Z, Morris SW, Coffin CM, Hill DA. Anaplastic lymphoma kinase (ALK) expression in the inflammatory myofibroblastic tumor: a comparative immunohistochemical study. Am J Surg Pathol. 2001 Nov;25(11):1364-71. PMID: #11684952#
Coffin CM, Patel A, Perkins S, et al. ALK1 and p80 expression and chromosomal rearrangements involving 2p23 in inflammatory myofibroblastic tumor. Mod Pathol 2001;14:569–576.
Griffin CA, Hawkins AL, Dvorak C, et al. Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors. Cancer Res 1999;59:2776–2780.
Coffin CM, Watterson J, Priest JR, Dehner LP. Extrapulmonary inflammatory myofibroblastic tumor (inflammatory pseudotumor). A clinicopathologic and immunohistochemical study of 84 cases. Am J Surg Pathol. 1995 Aug;19(8):859-72. PMID: #7611533#
Souid AK, Ziemba MC, Dubansky AS, et al. Inflammatory myofibroblastic tumor in children. Cancer 1993;72:2042–2048.